New Zealand Becomes Second Country to Approve MDMA for PTSD Treatment

New Zealand has become the second country in the world, following Australia in 2023, to authorize the prescription of pharmaceutical-grade MDMA for patients suffering from severe post-traumatic stress disorder (PTSD). Medsafe, the nation’s medicines regulator, granted the approvals to psychiatrists Dr. Gary Wynn in Wellington and Dr. Tom Paterson in Auckland after they completed a rigorous regulatory process lasting more than a year.

Deputy Prime Minister David Seymour championed the decision, highlighting the severity of PTSD and the limitations of current treatments. “PTSD ruins lives and is difficult to treat,” Seymour stated, noting the potential of psychedelic-assisted therapy. He also referenced his previous support for psilocybin approval for severe depression, affirming the government’s commitment to expanding access to innovative medical treatments.

The regulatory approval is grounded in data from two pivotal Phase 3 international trials conducted by the US-based Multidisciplinary Association for Psychedelic Studies and sponsored by Lykos Therapeutics. A 2021 study reported that 88% of participants with severe PTSD experienced clinically significant improvement, with 67% no longer meeting diagnostic criteria. A subsequent 2023 trial involving moderate-to-severe cases found that 71.2% of those treated no longer met PTSD diagnostic standards by the study’s conclusion.

These findings contrast with the US Food and Drug Administration’s 2024 rejection of the therapy. US regulators cited insufficient evidence regarding safety and effectiveness, specifically pointing to concerns that participants with prior MDMA experience may have introduced expectancy bias into the trial results.

Addressing safety protocols, New Zealand’s Ministry of Health emphasized that the treatment will be strictly controlled. MDMA will not be provided as take-home medication; instead, it must be administered in a clinical setting under the supervision of an authorized psychiatrist as part of a comprehensive treatment plan. Patients must be at least 18 years old to qualify for the therapy.